Thanks BearDownAZ,

3-point MACE in REDUCE-IT placebo patients occured in 14.8% of patients after a median follow up of 4.9 years. Recall that EXAMINE and ELIXA trials had 3-point MACE event rates of about 12% at median follow up of 18 months and 13% at median follow up of 25 months. EXAMINE and ELIXA were CVOTs in diabetics with requirements for recent ACS of within 90 days and 180 days, respectively. Since BETonMACE has additional low-HDL requirement and ACS event within 15-90 days requirement, I wouldn't be surprised to see placebo group in BETonMACE have a ~15% 3-point MACE event rate at median follow up of ~2 years.

Fot the guesstimated placebo group, what would 15% be equal to in per 100 patient years,... about 8%,...? What formula do I use to caluclate the median to the 100 patient years,...?

Thanks!!